» Articles » PMID: 22113443

Prevalence of Left-ventricular Hypertrophy in Hypertension: an Updated Review of Echocardiographic Studies

Overview
Journal J Hum Hypertens
Date 2011 Nov 25
PMID 22113443
Citations 119
Authors
Affiliations
Soon will be listed here.
Abstract

Left-ventricular hypertrophy (LVH) is a cardinal manifestation of hypertensive organ damage associated with an increased cardiovascular (CV) risk. We reviewed recent literature on the prevalence of LVH, as assessed by echocardiography, in order to offer an updated information on the magnitude of subclinical alterations in LV structure in contemporary human hypertension. A MEDLINE search using key words 'left ventricular hypertrophy', 'hypertension', 'echocardiography' and 'cardiac organ damage' was performed in order to identify relevant papers. Full articles published in English language in the last decade, (1 January 2000-1 December 2010), reporting studies in adult or elderly individuals, were considered. A total of 30 studies, including 37,700 untreated and treated patients (80.3% Caucasian, 52.4% men, 9.6% diabetics, 2.6% with CV disease) were considered. LVH was defined by 23 criteria; its prevalence ranged from 36% (conservative criteria) to 41% (less conservative criteria) in the pooled population. LVH prevalence was not different between women and men (range 37.9-46.2 versus 36.0-43.5%, respectively). Eccentric LVH was more frequent than concentric hypertrophy (range 20.3-23.0 versus 14.8-15.8, respectively, P<0.05); concentric phenotype was found in a consistent fraction (20%) of both genders. Despite the improved management of hypertension in the last two decades, LVH remains a highly frequent biomarker of cardiac damage in the hypertensive population. Our analysis calls for a more aggressive treatment of hypertension and related CV risk factors leading to LVH.

Citing Articles

Cinnamic acid alleviates hypertensive left ventricular hypertrophy by antagonizing the vasopressor activity and the pro-cardiac hypertrophic signaling of angiotensin II.

Cui Y, Yang Y, Tang X, Wang P, Cui J, Chen Y Front Pharmacol. 2025; 16:1555991.

PMID: 40028160 PMC: 11868102. DOI: 10.3389/fphar.2025.1555991.


Burden trends and future predictions for hypertensive heart disease attributable to non-optimal temperatures in the older adults amidst climate change, 1990-2021.

Xu C, Nie X, Xu R, Han G, Wang D Front Public Health. 2025; 12():1525357.

PMID: 39830174 PMC: 11738906. DOI: 10.3389/fpubh.2024.1525357.


Left ventricular hypertrophy in young hypertensives: the possible crosstalk of mTOR and angiotensin-II -a case-control study.

Oguntola B, Oguntola S, Ojo O, Ukpabio P, Omoaghe A, Olaniyi K BMC Cardiovasc Disord. 2025; 25(1):9.

PMID: 39780084 PMC: 11714912. DOI: 10.1186/s12872-025-04470-9.


Endurance Sports and Atrial Fibrillation: A Puzzling Conundrum.

Ostojic M, Ostojic M, Petrovic O, Nedeljkovic-Arsenovic O, Perone F, Banovic M J Clin Med. 2025; 13(24.

PMID: 39768614 PMC: 11677941. DOI: 10.3390/jcm13247691.


Association of triglyceride glucose-body mass index and left ventricular hypertrophy in patients with IgA nephropathy: a retrospective study.

Jv M, Zhang J, Han Y, Yang A, Zhu Y Eur J Med Res. 2024; 29(1):627.

PMID: 39726054 PMC: 11670427. DOI: 10.1186/s40001-024-02234-3.